Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection
Tim R.H. Read

, Jørgen S. Jensen, Christopher K. Fairley, Mieken Grant, Jennifer A. Danielewski, Jenny Su, Gerald L. Murray, Eric P.F. Chow, Karen Worthington, Suzanne M. Garland, Sepehr N. Tabrizi, and Catriona S. Bradshaw
Author affiliations: Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia (T.R.H. Read, C.K. Fairley, M. Grant, E.P.F. Chow, K. Worthington, C.S. Bradshaw); Monash University, Melbourne, Victoria, Australia (T.R.H. Read, C.K. Fairley, G.L. Murray, E.P.F. Chow, C.S. Bradshaw); Statens Serum Institut, Copenhagen, Denmark (J.S. Jensen); Murdoch Children’s Research Institute, Parkville, Victoria, Australia (J.A. Danielewski, J. Su, G.L. Murray, S.M. Garland, S.N. Tabrizi); Royal Women’s Hospital, Parkville (J.A. Danielewski, J. Su, G.L. Murray, S.M. Garland, S.N. Tabrizi); University of Melbourne, Parkville (S.M. Garland, S.N. Tabrizi, C.S. Bradshaw)
Main Article
Table 2
Mycoplasma genitalium infections among 114 patients cured after 10 days of pristinamycin treatment, Melbourne Sexual Health Centre, Melbourne, Victoria, Australia, 2012–2016
Subgroup |
Pristinamycin failure, no. (%) |
Cured, no. (%, 95% CI) |
p value* |
Overall
|
29 (25)
|
85 (75, 66–82)
|
|
Dosage regimen |
|
|
|
Pristinamycin 2 g/d |
2 (22) |
7 (78, 40–97) |
0.91
|
Pristinamycin 3 g with doxycycline 200 mg/d |
14 (26) |
40 (74, 60–85) |
Pristinamycin 4 g/d
|
13 (25)
|
38 (75, 60–86)
|
Site of infection |
|
|
|
Urethral infection, M |
22 (29) |
55 (71, 60–81) |
0.20
|
Anorectal infection
|
4 (14)
|
24 (86, 67–96)
|
Patient sex |
|
|
|
F |
3 (27) |
8 (73, 39–94) |
1.0
|
M
|
26 (25)
|
77 (75, 65–83)
|
Patient signs/symptoms |
|
|
|
Symptomatic |
28 (29) |
70 (71, 61–80) |
0.07 |
Asymptomatic |
1 (6) |
15 (94, 70–100) |
Main Article
Page created: January 17, 2018
Page updated: January 17, 2018
Page reviewed: January 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.